Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research

Author(s): Anne Penttinen, Jofre Tenorio-Laranga, Anssi Siikanen, Markus Morawski, Steffen Roßner, J. Arturo Garcia-Horsman

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 10 , Issue 3 , 2011

Become EABM
Become Reviewer
Call for Editor


Inhibitors of prolyl oligopeptidase have been reported to be neuroprotective, especially in memory loss caused by lesion or disease. This enzyme has also been implicated in neurodegeneration. Although it was initially thought that prolyl oligopeptidase functioned to directly control of neuropeptide levels, emerging evidence points out in part that this peptidase modulates peptides which in turn regulate inflammatory responses. Here we review the recent literature which indicates a direct involvement of prolyl oligopeptidase in several inflammatory diseases. Neuroinflammation generates neurotoxins with a relevant role in neurodegenerative diseases, and it is within this toxin generation where prolyl oligopeptidase might have a role.

Keywords: Autoimmune disease, glial activation, neuroinflammation, neurodegeneration, prolyl oligopeptidase, POP, Antigen presenting cells, Bradykinin, Renin-angiotensin system, Ac-SDKP, COPD, Bronchiolitis Obliterans Syndrome, Rheumatoid Arthritis, Mycobacterium tuberculosis, Systemic Lupus Erythematosus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [340 - 348]
Pages: 9
DOI: 10.2174/187152711794653742
Price: $65

Article Metrics

PDF: 18